Search Results

April 23, 2013

Janssen Products, LP Modifies Prescribing Information For PROCRIT® (Epoetin alfa) In Chronic Kidney Disease

Revised prescribing information reflects FDA guidance to update labeling for all drugs within ESA class

April 18, 2013

Richard Petty Teams Up With Janssen Biotech to Launch Show Your Stripes for Prostate Cancer Awareness

Program Builds Prostate Cancer Awareness and Action in Support of America’s Veterans and Adds to Other Janssen Biotech Education Efforts for Men at High Risk, including Making Awareness a Priority (M.A.P.)

Innovative Medicine

April 8, 2013

Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration

Designation granted in the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with a genetic mutation, del17p Ibrutinib is an investigational oral Bruton’s tyrosine kinase inhibitor being studied in several B-cell malignancies

Innovative Medicine

April 3, 2013

Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study

First Results of Collaboration Between Veridex, LLC and Massachusetts General Hospital Published in Science Translational Medicine

Innovative Medicine

March 29, 2013

U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes

INVOKANA™ is the first in a new class of type 2 diabetes medications available in the United States In Phase 3 studies, INVOKANA™ improved blood glucose control and was associated with reductions in body weight and systolic blood pressure Janssen will partner with other Johnson & Johnson companies focused on diabetes to bring INVOKANA™ to healthcare professionals

Innovative Medicine

March 28, 2013